IELSG50

IELSG50Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma who are not eligible for chemotherapy
Participants required30
Investigator responsible(s)S. Luminari and W. Zhao
Objective(s)The primary objective of the IELSG50 trial is to test the efficacy of concurrent RT- Pembrolizumab in patients with limited-stage high-risk NK/T cell lymphoma who are not eligible or refuse to receive chemotherapy.
Lay summaryNasal NK/T cell lymphoma is a rare non-Hodgkin’s lymphoma associated with the Epstein-Barr virus and common in Asian and South American populations.
It often affects areas such as the nose, skin or digestive tract and can be difficult to treat in high-risk patients. Radiation therapy (RT) shows good local results, and new drugs such as pembrolizumab offer promising low-toxicity options.
High-risk patients who can’t tolerate or refuse chemotherapy may benefit from a combination of RT and pembrolizumab. This combined approach is being studied as a potential first-line treatment to improve outcomes in high-risk cases with localized disease

Home | Go to Studies

Top